Abstract
High-risk neuroblastoma (NB) represents a problematic tumor phenotype associated with a dreary outlook. Modern molecular achievements over the last decade have seen the increase and implementation of omics technologies in oncology that promises to provide for a deeper comprehension of complex tumor pathways. The emerging concept of analyzing NB-specific omics profiles to better understand and define the behavior of advanced-stage tumors along with providing direct and targeted therapy may ultimately translate into improved outcomes for high-risk NB. Knowledge of NB proteomics has gradually become available, but the challenge remains to integrate data obtained from different levels of biological organization. In this review, we provide an overview of the proteomics-based techniques that can be used to advance and accelerate the discovery of novel molecular biomarkers for NB. By citing specific examples, we discuss how proteomics has contributed to the early detection of advanced-stage NB and minimal residual disease. We end by contemplating the emerging technologies that are likely to have a high impact on the field of NB in the near future.
Keywords: Neuroblastoma, proteomics, post-genomic era, biomarkers, minimal residual disease, metastatic tumor cells, 'omics technologies, systems biology
Current Proteomics
Title: Oncoproteomics of Neuroblastoma: A Blueprint for Future Progress
Volume: 7 Issue: 1
Author(s): Hari R. Kumar, Xiaoling Zhong, Robert J. Hickey, Linda H. Malkas and John A. Sandoval
Affiliation:
Keywords: Neuroblastoma, proteomics, post-genomic era, biomarkers, minimal residual disease, metastatic tumor cells, 'omics technologies, systems biology
Abstract: High-risk neuroblastoma (NB) represents a problematic tumor phenotype associated with a dreary outlook. Modern molecular achievements over the last decade have seen the increase and implementation of omics technologies in oncology that promises to provide for a deeper comprehension of complex tumor pathways. The emerging concept of analyzing NB-specific omics profiles to better understand and define the behavior of advanced-stage tumors along with providing direct and targeted therapy may ultimately translate into improved outcomes for high-risk NB. Knowledge of NB proteomics has gradually become available, but the challenge remains to integrate data obtained from different levels of biological organization. In this review, we provide an overview of the proteomics-based techniques that can be used to advance and accelerate the discovery of novel molecular biomarkers for NB. By citing specific examples, we discuss how proteomics has contributed to the early detection of advanced-stage NB and minimal residual disease. We end by contemplating the emerging technologies that are likely to have a high impact on the field of NB in the near future.
Export Options
About this article
Cite this article as:
Kumar R. Hari, Zhong Xiaoling, Hickey J. Robert, Malkas H. Linda and Sandoval A. John, Oncoproteomics of Neuroblastoma: A Blueprint for Future Progress, Current Proteomics 2010; 7 (1) . https://dx.doi.org/10.2174/157016410790979653
DOI https://dx.doi.org/10.2174/157016410790979653 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
Call for Papers in Thematic Issues
Mass spectrometry data acquisition and analysis for proteomics
The Thematic Issue on "Mass spectrometry data acquisition and analysis for proteomics" aims to explore the latest advancements and challenges in the field of proteomics through the lens of mass spectrometry. Proteomics, the large-scale study of proteins and their functions, plays a crucial role in understanding various biological processes and ...read more
Peptides: State-of-Art and Commercialisation Hurdles
The Editors of the Current Proteomics (CP) journal are highly privileged to welcome scientists to submit their scientific research and review articles to be considered for publication in the upcoming thematic issue. The topics should cover various aspects of peptides in regard to their synthetic methodologies, formulation approaches, pharmacological challenges, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ion Channels as Important Targets for Antiepileptic Drug Design
Current Drug Targets A Proteomic Analysis of Mitochondrial Complex III Inhibition in SH-SY5Y Human Neuroblastoma Cell Line
Current Proteomics Epigenetic Regulation of EMT: The Snail Story
Current Pharmaceutical Design Co-Treatment With Copper Compounds Dramatically Decreases Toxicities Observed With Cisplatin Cancer Therapy And The Anticancer Efficacy Of Some Copper Chelates Supports The Conclusion That Copper Chelate Therapy May Be Markedly More Effective And Less Toxic Than Cisplatin Therapy
Current Medicinal Chemistry Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Cancer Stem Cells – Are Surface Markers Alone Sufficient?
Current Stem Cell Research & Therapy Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets
Current Neuropharmacology Colostral Proline-Rich Polypeptides - Immunoregulatory Properties and Prospects of Therapeutic Use in Alzheimers Disease
Current Alzheimer Research Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
Current Radiopharmaceuticals Boron Nitride Nanotubes: Production, Properties, Biological Interactions and Potential Applications as Therapeutic Agents in Brain Diseases
Current Nanoscience Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design Pathophysiology of Transmissible Spongiform Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry Carbohydrate Antigens: Synthesis Aspects and Immunological Applications in Cancer
Mini-Reviews in Medicinal Chemistry Therapeutic Targeting of the Endoplasmic Reticulum in Alzheimers Disease
Current Alzheimer Research Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration
Current Neuropharmacology Strategies Targeting Soluble β-Amyloid Oligomers and their Application to Early Diagnosis of Alzheimer’s Disease
Current Alzheimer Research